Table 1.
Patient and procedure characteristics | |
---|---|
N | 4,152 |
Median patient age, years (range) | 53 (18–79) |
Median donor age, years (range) | 37 (5–77) |
Missing data | 2,344 |
Median year of transplantation (range) | 2,013 (2,011–2,015) |
Median interval from diagnosis to transplantation, range (days) | 296 (7–13,058) |
Donor type | |
HLA-identical sibling | 1,328 (32%) |
Unrelated | 2,824 (68%) |
HLA-matched | 1,491 (72%) |
HLA-mismatched | 576 (28%) |
Missing data | 757 |
Donor/recipient gender | |
Female to male | 851 (21%) |
Other combination | 3,255 (79%) |
Missing data | 46 |
Donor/recipient CMV serological status | |
Negative/negative | 1,089 (27.5%) |
Other | 2,871 (72.5%) |
Missing data | 192 |
Diagnosis | |
Acute leukemia | 2,091 (50%) |
Chronic leukemia | 432 (10%) |
Lymphoma | 560 (14%) |
Plasma cell disorders | 185 (5%) |
MDS/MPN | 884 (21%) |
Disease risk status at alloHCT* | |
High risk | 1,387 (35%) |
Low/moderate risk | 2,625 (65%) |
Missing | 140 |
Previous autoHCT | |
No | 3,645 (88%) |
Yes | 507 (12%) |
Source of stem cells | |
Bone marrow | 356 (9%) |
Peripheral blood | 3,796 (91%) |
In vivo T-cell depletion | |
No | 1,870 (45.7%) |
Yes | 2,223 (54.3%) |
Conditioning intensity | |
Myeloablative | 2,047 (49%) |
Reduced intensity | 2,096 (51%) |
Missing data | 9 |
Type of conditioning | |
Chemotherapy-based | 3,027 (73%) |
Total body irradiation-based | 1,122 (27%) |
Missing data | 3 |
Economic and socioeconomic indices | Median (range) |
Current HCE, range (Euro) | 4,955 (465–9,720) |
Median HCE as % of GDP | 11.1 (3.7–12) |
Median private HCE, range (Euro) | 1,087 (103–3,168) |
Median public HCE, range (Euro) | 3,868 (308–8,285) |
Median no. teams per 1 million inhabitants | 1.09 (0.03–1.62) |
Median no. teams per 1,000 km2 | 0.20 (0.00–0.59) |
Median HDI | 0.88 (0.74–0.94) |
Median no. alloHCT** between 2004 and 2008 | 13.5 (2.0–35.0) |
MDS indicates myelodysplastic syndrome; MPN, myeloproliferative neoplasms; HCE health care expenditure; HDI, human development index; GDP, gross domestic product per capita.
For the purpose of this study the definition of high risk related to underlying disease was defined as follows: acute leukemias and lymphomas with active disease, chronic myeloid leukemia in acceleration phase or in blast crisis, myelodysplastic syndromes and myeloproliferative neoplasms not responding to preceding therapy.
Refers to transplantation procedures according to selection criteria chosen for this study.